Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas 24/7 Wall St. Biogen also is partnering with AbbVie Inc. (NYSE: ABBV) in Phase III trials for Daclizumab. Credit Suisse has a $255 dollar price target on this top name. The consensus price target is $247.50. Other large companies that will figure into the growing MS ... |
